KRAS and neoplasm: RMC-7977 exhibited optimal efficacy against RAS-addicted neoplasms characterized by diverse RAS genotypic profiles in preclinical oncology models, showing pronounced activity in models harboring KRAS codon 12 mutations (KRASG12X) 154.